Cytel other research news

The San Diego company received a $3.3 million grant from the National Institute of Allergy and Infectious Diseases to develop a peptide-based immunotherapeutic vaccine for HIV using CYTL's modular Theradigm technology.

Under the Strategic Programs for Innovative Research on AIDS Treatment (SPIRAT) grant, CYTL will collaborate with investigators at Massachusetts General Hospital to develop a vaccine to control or eradicate chronic retroviral infection through the induction of virus-specific killer T cells. CYTL will receive $1.8 million from the grant, while the hospital will receive the remaining $1.5 million. ...